Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gemma Modinos

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
JAMA Psychiatry|November 15, 2018
Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for PsychosisMatthijs G Bossong, Mathilde Antoniades, Matilda Azis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 7, 2021
GABA<sub>A</sub> and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophreniaAmanda Kiemes, Felipe V Gomes, Diana Cash, et al.
Translational Psychiatry|December 1, 2021
Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic functionPaul Allen, Emily J Hird, Natasza Orlov, et al.
Translational Psychiatry|November 11, 2021
Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic functionPaul Allen, Emily J Hird, Natasza Orlov, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 17, 2019
Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging studyOliver D Howes, Ilaria Bonoldi, Robert A McCutcheon, et al.
The International Journal of Neuropsychopharmacology|October 12, 2017
Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal SymptomsGemma Modinos, Fatma Simsek, Jamie Horder, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 4, 2021
Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomesGemma Modinos, Anja Richter, Alice Egerton, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 15, 2018
Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosisGemma Modinos, Fatma Şimşek, Matilda Azis, et al.
Schizophrenia Bulletin|December 14, 2022
Speech Illusions in People at Clinical High Risk for Psychosis Linked to Clinical OutcomeEmily J Hird, Noriyuki Ohmuro, Paul Allen, et al.
Frontiers in Psychiatry|March 27, 2023
Parsing neurobiological heterogeneity of the clinical high-risk state for psychosis: A pseudo-continuous arterial spin labelling studyDominic Oliver, Cathy Davies, Fernando Zelaya, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
JAMA Psychiatry|November 15, 2018
Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for PsychosisMatthijs G Bossong, Mathilde Antoniades, Matilda Azis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 7, 2021
GABA<sub>A</sub> and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophreniaAmanda Kiemes, Felipe V Gomes, Diana Cash, et al.
Translational Psychiatry|December 1, 2021
Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic functionPaul Allen, Emily J Hird, Natasza Orlov, et al.
Translational Psychiatry|November 11, 2021
Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic functionPaul Allen, Emily J Hird, Natasza Orlov, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 17, 2019
Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging studyOliver D Howes, Ilaria Bonoldi, Robert A McCutcheon, et al.
The International Journal of Neuropsychopharmacology|October 12, 2017
Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal SymptomsGemma Modinos, Fatma Simsek, Jamie Horder, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 4, 2021
Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomesGemma Modinos, Anja Richter, Alice Egerton, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 15, 2018
Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosisGemma Modinos, Fatma Şimşek, Matilda Azis, et al.
Schizophrenia Bulletin|December 14, 2022
Speech Illusions in People at Clinical High Risk for Psychosis Linked to Clinical OutcomeEmily J Hird, Noriyuki Ohmuro, Paul Allen, et al.
Frontiers in Psychiatry|March 27, 2023
Parsing neurobiological heterogeneity of the clinical high-risk state for psychosis: A pseudo-continuous arterial spin labelling studyDominic Oliver, Cathy Davies, Fernando Zelaya, et al.
Pageof 9